https://www.selleckchem.com/products/cay10603.html
If approved, ibrexafungerp will be the first new antifungal agent available for the treatment of VVC in more than 20years and the only oral, non-azole antifungal approved for women suffering from VVC. Ibrexafungerp addresses several unmet needs with existing antifungal drugs as a first in a new class of antifungal agents with a novel mechanism of action demonstrating no antifungal cross resistance with azoles, and fungicidal activity against Candida spp., including fluconazole-resistant species. Some of the key attributes of ibrexafung
Curtir
Comentario
Compartilhar
